Literature DB >> 12584106

Protecting subjects, preserving trust, promoting progress I: policy and guidelines for the oversight of individual financial interests in human subjects research.

.   

Abstract

In December 2001, the AAMC Task Force on Financial Conflicts of Interest in Clinical Research released this report, the first of two (both published in this issue of Academic Medicine). This report focuses on gaps in existing federal financial disclosure regulations of individual conflicts of interests, finding that additional scrutiny is recommended in two areas: human subjects research and privately sponsored research. The task force suggests that when potential conflicts exist, a conflicts of interest committee should apply a rebuttable presumption against engaging in human subjects research. The task force recommends that the circumstances giving rise to the presumption against the proposed activity be balanced against compelling circumstances in favor of the conduct of the research. The AAMC task force delineates core principles to guide institutional policy development. First, an institution should regard all significant financial interests in human subjects research as requiring close scrutiny. Second, in the event of compelling circumstances, an individual holding a significant financial interest may be permitted to conduct the research. Whether circumstances are deemed compelling will depend in each case upon the nature of the science, the nature of the interest, how closely the interest is related to the research, and the degree to which the interest may be affected by the research. Four other core principles for development of institutional policies are identified in the report, pertaining to reporting, monitoring, management of conflicts, and accountability.

Entities:  

Keywords:  Association of American Medical Colleges; Biomedical and Behavioral Research

Mesh:

Year:  2003        PMID: 12584106

Source DB:  PubMed          Journal:  Acad Med        ISSN: 1040-2446            Impact factor:   6.893


  29 in total

1.  Emerging ethical issues in instructions to authors of high-impact biomedical journals.

Authors:  Michel C Atlas
Journal:  J Med Libr Assoc       Date:  2003-10

2.  Getting it right: industry sponsorship and medical research.

Authors:  Patricia Baird
Journal:  CMAJ       Date:  2003-05-13       Impact factor: 8.262

3.  How to dance with porcupines: rules and guidelines on doctors' relations with drug companies.

Authors:  Elizabeth Wager
Journal:  BMJ       Date:  2003-05-31

4.  Relationship between conflicts of interest and research results.

Authors:  Lee S Friedman; Elihu D Richter
Journal:  J Gen Intern Med       Date:  2004-01       Impact factor: 5.128

5.  Physician remuneration in industry-sponsored clinical trials: the case for standardized clinical trial budgets.

Authors:  Lorraine E Ferris; C David Naylor
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

6.  360 Degrees of human subjects protections in community-engaged research.

Authors:  Lainie Friedman Ross
Journal:  Sci Transl Med       Date:  2010-08-18       Impact factor: 17.956

7.  Challenges in ethics, safety, best practices, and oversight regarding HIT vendors, their customers, and patients: a report of an AMIA special task force.

Authors:  Kenneth W Goodman; Eta S Berner; Mark A Dente; Bonnie Kaplan; Ross Koppel; Donald Rucker; Daniel Z Sands; Peter Winkelstein
Journal:  J Am Med Inform Assoc       Date:  2010-11-12       Impact factor: 4.497

Review 8.  Evidence-based ethics for neurology and psychiatry research.

Authors:  Scott Y H Kim
Journal:  NeuroRx       Date:  2004-07

9.  Resident and faculty perceptions of conflict of interest in medical education.

Authors:  Peter Y Watson; Akshay K Khandelwal; Joseph L Musial; John D Buckley
Journal:  J Gen Intern Med       Date:  2005-04       Impact factor: 5.128

10.  Comparative outcome studies of clinical decision support software: limitations to the practice of evidence-based system acquisition.

Authors:  Gaurav Jay Dhiman; Kyle T Amber; Kenneth W Goodman
Journal:  J Am Med Inform Assoc       Date:  2015-02-08       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.